@prefix dcterms: . @prefix this: . @prefix sub: . @prefix prov: . @prefix pav: . @prefix orcid: . @prefix codebase: . @prefix version: . @prefix instance: . @prefix process: . @prefix np: . @prefix rdfs: . @prefix xsd: . @prefix has-source: . @prefix d: . @prefix dv: . @prefix dr: . @prefix npx: . sub:head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:publicationInfo; a np:Nanopublication . } sub:assertion { d:DB00477 dv:ddi-interactor-in dr:DB00477_DB01624 . d:DB01624 dv:ddi-interactor-in dr:DB00477_DB01624 . dr:DB00477_DB01624 dcterms:identifier "drugbank_resource:DB00477_DB01624"; dcterms:title "DDI between Chlorpromazine and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Chlorpromazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if chlorpromazine is initiated, discontinued or dose changed."@en; a dv:Drug-Drug-Interaction; rdfs:label "DDI between Chlorpromazine and Zuclopenthixol - Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Chlorpromazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if chlorpromazine is initiated, discontinued or dose changed. [drugbank_resource:DB00477_DB01624]"@en . } sub:provenance { sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 . } sub:publicationInfo { sub:signature.MC0CFQCKecsGM1wv npx:hasPublicKey "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"; npx:hasSignature "MC0CFQCKecsGM1wv3Hu/0gXKnA/3l8u9ogIUHmzaa7Gpt1W+QKNsdt+7aeVQzGc="; npx:signedBy instance: . this: dcterms:created "2018-03-30T11:12:36.456+02:00"^^xsd:dateTime; dcterms:license ; npx:hasSignatureElement sub:signature.MC0CFQCKecsGM1wv; prov:wasGeneratedBy process: . instance: prov:specializationOf codebase:; prov:wasAttributedTo orcid:0000-0002-1267-0234 . process: dcterms:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11"; prov:used version:; prov:wasAssociatedWith instance:; prov:wasStartedBy orcid:0000-0002-1267-0234 . version: dcterms:isVersionOf codebase:; pav:version "eda7951a5f6c622c5d2132f50c3093138484a349"; prov:wasAttributedTo orcid:0000-0002-1267-0234 . }